

CMBI Credit Commentary – HPDLF

Hopson: Repayment track records count

Buy on HPDLFs; the CBs are attractive lower-beta and short-tenor plays

Table 1: Summary of outstanding offshore bonds

	O/s amt (USD mn)	Offer price	YTM	Maturity
HPDLF 8 01/06/23 CBs	250	86.9	57.0%	6/1/2023
HPDLF 6.8 12/28/23	237.5	69.3	39.4%	28/12/2023
HPDLF 7 05/18/24	300	61.0	41.5%	18/5/2024

We maintain buy on HPDLFs in view of its adequate liquidity profile, high asset quality, large offshore investment portfolio and manageable debt maturity profile. In particular, we consider HPDLF 8%'23, the CBs due 6 Jan'23, attractive low-beta and short-tenor plays.

Hopson has proven track records in full repayments even in a challenging operating environment and an unfavourable capital market. It repaid, rather than refinanced, CBs of RMB1.8bn in Feb'10, straight bonds of USD350mn and USD300mn in Sep'12 and Jan'18 in a challenging market environment. In Jun and Jul'22, it repaid 2 offshore bonds totalled cUSD1.1bn. HPDLFs rebounded 5-10pts since the recent lows in early-mid Aug'22. That said, offered at 87.1, 69.3 and 61.0, HPDLF 8%'23 (CBs), 6.8%'23 and 7%'24 are trading at YTM of 57.0%, 39.4% and 41.5%, respectively. We consider Hopson a survivor for the sector and believe that the current valuations of HPDLFs offer attractive risk-return profile.

Weaker but relatively resilient 1H22 results

Excluding investment losses and fair value gain of investment properties, Hopson's recurring revenue increased 35.4% to HKD15.0bn but recurring gross profit and EBIT lowered 4.6% and 12.1% to HKD4.9bn and HKD3.2bn, respectively. These reflected the lower profit margin of recognized property sales because of higher land costs and lower contribution from property management resulting from the impact of COVID-19. Its adj. gross and EBIT margin narrowed to 32.6% and 21.6% in 1H22 from 46.2% and 33.3%, respectively. Hopson expects its gross margin for property sales to be 25-30% over the coming 1-2 years. Hopson's 1H22 results, albeit weakened, were relatively resilient compared with those of its peers.

Hopson maintains the FY22 contract sales target at RMB40bn (cHKD45bn). In 8M22, its contract sales were RMB20.9bn, completed c52% of the full year target. Despite the 23.2% yoy decline in property pre-sales for the 8M22, its sales decline is relatively modest. For the 35 developers under our radar, the average yoy decline in contract sales for 8M22 was 48%.

Glenn Ko, CFA 高志和
 (852) 3657 6235
 glennko@cmbi.com.hk

CMBI Fixed Income
 fis@cmbi.com.hk

Offshore investment portfolio offers an alternative liquidity source

Table 2: Summary of investment portfolio

HKD mn	2H20	1H21	2H21	1H22
Investment income	5,194.1	5,007.1	-7,971.8	-1,819.6
Current financial assets	22,020.7	27,120.2	6,133.8	2,634.0
Non-current financial assets	6,143.2	5,770.8	6,389.6	5,319.3
Financial assets	28,163.9	32,891.0	12,523.4	7,953.3
Margin loan	9,163.8	10,170.2	3,391.7	1,454.1
Estimated LTV	32.5%	30.9%	27.1%	18.3%
Investments in JVs	11,480.0	12,071.9	8,874.9	8,776.3

Hopson booked investment losses (on revenue line) of HKD1.8bn in 1H22 and HKD8.0bn in 2H21. Over the 12-month to Jun'22, the investment loss totalled HKD9.8bn. That said, Hopson reported investment gain of HKD13.9bn for the 18-month to Jun'21.

The book value of its financial assets was HKD8.0bn, out of these, HKD2.6bn were booked under current financial assets which were mainly HK-listed equities. The non-current financial assets were mainly pre-IPO and PE investments. As per our discussions with Hopson, it had divested part of investments facing market volatilities in 2H21 and 1H22, reflected in the commensurate decline in margin loan. The positions in non-current financial assets were largely stable.

Based on public disclosure (for listed investments of >5% of outstanding shares), the market value of Hopson's listed investments in HKEX is c HKD4.6bn, including the 9.1% stakes in Ping An Healthcare of cHKD2.4bn booked under investments in JVs. We estimate that the value of its financial investments and listed investments in Ping An Healthcare to be over HKD10bn. Even excluding margin loans of HKD1.5bn, these offshore investments represent good alternative liquidity sources.

Debt reduction continues with demonstrated repayment records

Table 3: Key financial figures

HKD mn	Dec'20	Jun'21	Dec'21	Jun'22
Cash on hand	29,650.1	42,855.0	36,312.3	28,262.0
Current financial investments	22,020.7	27,120.2	6,133.8	2,634.0
ST debts	27,084.8	37,825.6	31,979.4	31,835.7
Net debts	87,766.0	83,503.7	83,042.5	77,429.7
Net gearing	89.7%	76.0%	73.5%	68.3%
Adj. liab/asset	64.4%	63.2%	63.2%	60.0%
Unrestricted cash/ST debts	1.0x	1.1x	0.9x	0.8x
Cash/ST debts	1.1x	1.1x	1.1x	0.9x
(Cash+current financial investments)/ST debts	1.9x	1.8x	1.3x	1.0x
3 Red Lines	Green	Green	Green	Yellow

Hopson continues the deleveraging trend since 1H21 with net debt lowered 6.8% to HKD77.4bn in 1H22. Its net gearing and adj. liab/assets ratios further improved to 68.3% and 60.0% in Jun'22 while cash/ST debts ratio weakened moderately to 0.9x given the lower cash on hand. Hopson was in yellow camp (down from green) under the 3 Red Lines. Nonetheless, we take comfort from its financial investments and manageable offshore debt maturities. Factoring into the current financial investments, its cash and current financial/ST debts is 1.0x. After the repayment of offshore bonds of HKD720mn in Jul'22, Hopson has 3 outstanding offshore bonds totalled USD787.5mn (see Table 1). The next offshore maturity will be the CBs of USD250mn due Jan'23. We believe that

Hopson will have adequate liquidity to cover its near-term maturities. Additionally, Hopson has been gradually opening up the access to onshore CMBS since 2018 through collateralization of its high quality investment properties since 2018. As at Jun'22, its investment property portfolio was valued at cHKD85bn with 95% of GFA in T1 cities and LTM rental income of HKD4.2bn. Its o/s CMBS was HKD13.3bn. Assuming a LTV of 50%, headroom for additional CMBS will be cHKD29bn (cUSD3.7bn). We take additional comfort from Hopson's proven track records in full repayments even in challenging times.

CMB International Global Markets Limited

Fixed Income Department

Tel: 852 3761 8867/ 852 3657 6291

fis@cmbi.com.hk

CMB International Global Markets Limited("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclosure:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US, institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.